CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. Co.'s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. We show 40 historical shares outstanding datapoints in our CTSO shares outstanding history coverage, used to compute CTSO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CTSO market cap history over the course of time is important for investors
interested in comparing CTSO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CTSO versus a peer is one thing; comparing
CTSO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CTSO can fluctuate over the course of history.
With this page we aim to empower investors researching CTSO by allowing them to research the CTSO market cap history. |
Free CTSO Email Alerts:
Video: The Importance of Market Cap
